The global ovarian cancer treatment drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The rising prevalence of ovarian cancer is the major factor accelerating market growth. Ovarian cancer is the second most common gynecologic cancer in the US. The American Cancer Society (ACS) estimates that there will be nearly 19,880 women receiving a new diagnosis of ovarian cancer in the US. Growing consumption of contraceptives and declining use of hormonal therapies are resulting in a reduced mortality rate due to ovarian cancer. The major factor that is expected to accelerate the growth of the market during the forecast period includes the increasing incidence of ovarian cancer. The need for more effective treatment options is another factor that is fuelling the growth of the market. While the market is dominated by generics such as paclitaxel and carboplatin, it is expected that drugs such as Bevacizumab (Avastin), Pazopanib (Votrient) would boost the growth of this market. The development of drugs with improved efficacy is a challenge for this market. The opportunity for this market lies in developing new drugs for treating ovarian cancer.

The current research in ovarian cancer is focused on using novel treatments such as immunotherapy, targeted therapy, and most importantly combination regimens. Immuno-oncologic agents have shown promising results with improved survival and lower toxicity. However, a single-agent response rate of PD-1/ PD-L1 molecules such as Opdivo and Keytruda for ovarian cancer treatment is less than 20.0%. Combination therapies, specifically those including checkpoint inhibitors, are poised to be introduced in the first-line setting to target major unmet needs including overcoming tumor resistance, improving progression-free survival, and maintaining the quality of life.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type 

o By Application 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape: F. Hoffman La-Roche AG, GlaxoSmithKline plc, and AstraZeneca plc, among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Ovarian Cancer Treatment Drugs Market Report by Segment

By Type

• Platinum Anti-Cancer Drugs

• Fluoropyrimidine

• Anthracycline Antibiotics

• Therapeutic Antibody

• Small Molecules Drug

• Aromatase Inhibitors

• Anti-Estrogens

By Application

• Hospitals

• Clinics

• Drug Store

• Others

Global Ovarian Cancer Treatment Drugs Market by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa